Jump to:
Novartis has launched a new interleukin inhibitor, Ilaris (canakinumab) for the treatment of cryopyrin-associated periodic syndromes (CAPS).
It is suitable for use in adults, adolescents and children aged 4 years and older with a body weight above 15kg. The recommended dose is 150mg in patients over 40kg and 2mg/kg for those between 15 and 40kg.
Ilaris is administered as a single dose via subcutaneous injection once every eight weeks. Treatment should be initiated and supervised by a specialist experienced in the diagnosis and management of CAPS.
Further information: Novartis Pharmaceuticals
There are currently no comments.
You must log in to comment on articles.
New users can register here free for full access.
Educational resource for the learning and teaching of the
GP curriculum
Cumulative list of products discontinued from the UK market
in 2010
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
A Haymarket Publication © 1957 – 2010
